



Institutional Biosafety Committee Meeting Minutes

Date: August 29, 2025
Time: 3:00 pm
Location: Via Zoom
Attendees: Tim Allen, Chairperson
Ting Wang, Public Health
Yuan Liu, Chemistry
Amita Quadros, Community Member
Tamece Knowles, EH&S Director (ALT)
Gina Gallian Oubrar, Associate Director, EH&S
*Angel Rayo, Research Integrity

*** Ex Officio (Non-Voting)**

Proceedings: Dr. Tim Allen, IBC Chairperson, called the meeting to order at 3:00 pm

Acceptance of Agenda

- The committee accepted the agenda for the meeting.

Announcements

N/A

Approval of Minutes

- The minutes from the June 27, 2025, meeting were approved.
Motion: A motion was made to **approve**.
Action: The minutes were approved.
Vote: Yes – 5, No – 0, Abstain – 0, Conflict – 0

Amended Protocols

1. Reference# 300535: “Restoring mucociliary clearance apparatus to mitigate lung inflammation in the context of HIV and cigarette smoke,” submitted by ██████████.

- a. Source organism: *Streptococcus thermophilus*, Streptococcus; *Streptomyces alboniger*, Streptomyces alboniger (Puromycin resistance); Human Immunodeficiency Virus, HIV; *Mus Musculus*, Mouse; *E.coli K12 strain*, E. coli; *Homosapiens, airway epithelial cells*, Human. Appendix B. III. Risk Group 3 (RG3).
- b. To be expressed in: *Homosapiens: Primary normal human bronchial epithelial (NHBE) cells and HEK 293 cells.*, Human; *Mus Musculus*, Mouse; *E.coli K12 strain*, E. coli. Appendix B. II. Risk Group 2 (RG2).
- c. Inserted DNA Sequence: Cas9 protein, Puromycin resistance gene, sgRNA is a synthetic RNA molecule that is approximately 90 nucleotides long. It is chemically synthesized using regular nucleotides as a small RNA molecule.
- d. Vectors: Edit-R CAG-PuroR-Cas9 expression plasmid DNA (Horizon Discovery, formerly Dharmacon, Cat # U-005600-120), AAV2/6 vectors will be obtained from vector biolabs. They will clone and package as a service.
- e. Method of insertion: Injection and Transfection.
- f. Containment Conditions: [REDACTED].
- g. Citi Training: All individuals have completed the required CITI trainings.
- h. Applicable section of NIH guidelines: Section III-D-3: Infectious DNA or RNA viruses

Risk Group 3 (RG3) - Viruses and Prions

Agents that are associated with serious or lethal human disease for which preventive or therapeutic interventions may be available (high individual risk but low community risk).

Appendix G-II-B-3-a. Biological safety cabinets (Class I or II) or other appropriate personal protective or physical containment devices are used

- i. Section 1.2 – All amendment changes in the protocol need to be listed to the section.
- j. Section 1.3 – *Change in Biosafety level, Procedural Changes, and Study Personnel* need to be selected in the section.
- k. Section 2.11.1.1 – The external associates non-FIU IBC approval memo needs to be attached to the section.
- l. Section 3.1.1.4 – The original award number needs to be re-added to the section.
- m. Section 3.3 – The project start date needs to be edited to it's original start date.
- n. Section 3.5 – The section needs to describe all the proposed changes in this amendment to the section, including source materials, host organisms, and vector systems.
- o. Section 6.2 – The updated IACUC approval memo needs to be attached to the section.
- p. Section 7.2 – The section needs to clarify if HIV or EcoHIV will be used and what human cells will be used.
- q. Section 7.4.7.1 – The PI needs to clarify how the mice are genetically modified.
- r. Section 7.8 – All infectious viruses need to be listed in the section.

- s. Section 8.1 – The containment/decontamination SOP needs to be updated to add new EH&S reporting link, remove old training link, and update the list of EH&S training.

Motion: A motion was made to **table** the protocol and return for modification.

Action: The protocol was **tabled**.

Vote: Yes – 5, No – 0, Abstain – 0, Conflict – 0

New Protocols

1. Reference# 300577: “Pathophysiology mechanisms and therapeutic interventions in mouse models of traumatic brain injury.” submitted by [REDACTED]

- a. Source organism: *Dependoparvovirus and AAV9*, Adeno-associated virus; Aequorea Victoria, Green-fluorescent protein. Appendix B. I. Risk Group 1 (RG1).
- b. To be expressed in: *Mus musculus*, Mouse. Appendix B. I. Risk Group 1 (RG1).
- c. Inserted DNA Sequence: Cas9 gene from *Streptococcus pyogenes* and GFP from *Aequorea victoria*
- d. Vectors: The PAD4 CRISPR All-in-one AAV virus (with saCas9) (Mouse; Serotype9) (pAAV-PGK-saCas9-U6-sgRNAsa) and scrambled CRISPR/Cas9 AAV (Control CRISPR; Cat. No. K079), will be purchased from Applied Biological Materials Inc (Richmond, BC, Canada).
- e. Method of insertion: Injection.
- f. Containment Conditions: [REDACTED].
- g. Citi Training: All individuals have completed the required CITI trainings.
- h. Applicable section of NIH guidelines: Section III-D-4: Genome

Appendix B-I Risk Group 1 (RG1) Agents

RG1 agents are not associated with disease in healthy adult humans.

Appendix G-II-A-3-a. Special containment equipment is generally not required for manipulations of agents assigned to BL1

- i. Section 2.14 – The FIU activity number needs to be included if received.
- j. Section 3.1 – The research grant proposal needs to be attached.
- k. Section 3.6 – The serotypes need to be included in the section.
- l. Section 4.17 – *No* needs to be selected.
- m. Section 5.2 – The PI needs to clarify if another location will be used.
- n. Section 6.2 – The IACUC approval memo needs to be attached.
- o. Section 7.1 - *Virus-Animal* needs to be unselected.
- p. Section 8.1 – The containment/decontamination SOP needs to be updated to add new EH&S link.

Motion: A motion was made to **approve** pending minor modifications.

Action: The protocol was **approved** pending modifications.

Vote: Yes – 5, No – 0, Abstain – 0, Conflict – 0

Revised Protocols

N/A

Renewed Protocols

N/A

Administrative Business

N/A

Meeting adjourned at 3:52 pm.